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Abstract
Constitutional MLH1 methylation (epimutation) is a rare cause of Lynch syndrome. Low-level methylation (≤ 10%)
has occasionally been described. This study aimed to identify low-level constitutional MLH1 epimutations and
determine its causal role in patients with MLH1-hypermethylated colorectal cancer.
Eighteen patients with MLH1-hypermethylated colorectal tumors in whom MLH1methylation was previously undetected in
blood by methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) were screened for MLH1
methylation using highly sensitive MS-melting curve analysis (MS-MCA). Constitutional methylation was characterized by
different approaches.
MS-MCA identified one patient (5.6%) with low-level MLH1methylation (~ 1%) in blood and other normal tissues, which was
confirmed by clonal bisulfite sequencing in blood. The patient had developed three clonally related gastrointestinal MLH1-
methylated tumor lesions at 22, 24, and 25 years of age. The methylated region in normal tissues overlapped with that
reported for other carriers of constitutional MLH1 epimutations. Low-level MLH1methylation and reduced allelic expression
were linked to the same genetic haplotype, whereas the opposite allele was lost in patient’s tumors. Mutation screening of
MLH1 and other hereditary cancer genes was negative.
Herein, a highly sensitive MS-MCA-based approach has demonstrated its utility for the identification of low-
level constitutional MLH1 epigenetic mosaicism. The eventual identification and characterization of additional
cases will be critical to ascertain the cancer risks associated with constitutional MLH1 epigenetic mosaicism.
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Introduction
Recent findings have indicated that underlying epimuta-
tions of certain genes in the normal tissue are associated
with an elevated risk of particular tumor types [1–5].
This indicates that epigenetic events, apart from genetic
alterations, maybe the initial step in the carcinogenesis
process for these tumors [6]. When epimutations predis-
posing to disease are widely distributed across normal
tissues, they are called constitutional epimutations.
Lynch syndrome (LS) is characterized by an increased
risk for colorectal cancer (CRC) as well as other cancers
(stomach, small intestine, and endometrium among
others) [7]. It is mainly caused by germline genetic muta-
tions in a mismatch repair (MMR) gene (MLH1, MSH2,
MSH6, or PSM2). In a small proportion of patients, LS is
caused by a MLH1 constitutional epimutation, in which
monoallelic hypermethylation of the promoter CpG island
throughout normal tissues is linked to a constitutional
allele-specific silencing [5].
Ninety-seven index cases with a constitutional MLH1
epimutation have been reported so far [8–12]. Most are
considered primary, arising apparently de novo and re-
versible between generations, whereas secondary epimu-
tations are associated with a genetic variant in cis.
Recently, we demonstrated that EPM2AIP1-MLH1 CpG
island is the sole differentially methylated region in pri-
mary MLH1 epimutation carriers [9]. Available evidence
suggests that constitutional epimutations cause a severe
LS phenotype, including early-onset and multiple pri-
mary tumors [5].
The level of constitutional methylation varies among
MLH1 epimutation carriers. Although the majority of
cases identified to date have shown hemiallelic MLH1
methylation in blood, variable levels of methylation have
frequently been reported (reviewed in [9]), including
seven cases harboring low methylation levels (≤ 10%)
[13–16]. Nevertheless, low-level MLH1 methylation in
blood has also been reported in healthy controls, con-
founding its interpretation [17]. Thus, the use of robust
and sensitive approaches is critical to determine the true
prevalence of constitutional epimutations and to ascer-
tain a putative role of mosaic MLH1 epimutation in can-
cer predisposition.
The main aim of this study was to identify patients with
low levels of constitutional epigenetic mosaicism of the
MLH1 gene using highly sensitive methylation analysis
techniques and explore its role in cancer predisposition.
Patients and methods
Patients and samples
Patients were identified through the Cancer Genetic
Counseling Units at the Catalan Institute of Oncology
from 1998 to 2016. Eighteen individuals presenting with
MLH1-methylated CRC before 50 years of age, or multiple
tumors before 60 years, were studied (Additional file 1:
Figure S1; Additional file 2: Table S1) after excluding two
previously reported bona fide constitutional MLH1 epi-
mutations [18]. Their levels of MLH1 methylation in PBL
(peripheral blood leukocytes) previously assessed by MS-
MLPA were between 0 and 4% at the Deng C and D re-
gions of the MLH1 promoter CpG island, hence were
below the limit of detection by this technique (10%) and
considered negative (Additional file 2: Table S1) [19].
Twenty case-matched healthy individuals (matched by
age, race, and geographic location) were included as con-
trols. In addition, 61 LS cases harboring MMR genetic
mutations, 12 constitutional MLH1 epimutation carriers,
and 41 healthy controls were included as reference groups
for comparative global methylome analyses [9]. Written
informed consent was obtained from all individuals, and
the ethics committee of the respective hospitals approved
the study. Sample processing is detailed in Additional file 3:
Supplementary Methods.
Methylation testing
The levels of methylation at the MLH1 promoter in
biological samples were assessed by several methods
(Additional file 3: Supplementary Methods and Additional
file 12: Table S5): (i) Methylation-specific multiplex
ligation-dependent probe amplification (MS-MLPA) using
the SALSA MLPA ME011 Mismatch Repair genes probe-
mix (MRC-Holland). (ii) Methylation-specific melting curve
analysis (MS-MCA): bisulfite-treated DNA was amplified
within the Deng C and D regions in a nested PCR on a
LightCycler 480 II; the analytical sensitivity of MS-MCA
was assessed using serial dilutions (100, 75, 50, 25, 10, 5, 4,
3, 2, and 1%) of the RKO cell line (biallelic MLH1 methyla-
tion; 100% methylated) into unmethylated (0% methylated)
Whole Genome Amplification (WGA) DNA. The analytical
sensitivity was 1% and 10% for the C and D regions, re-
spectively (Additional file 4: Figure S2A-B). (iii) Pyrose-
quencing: bisulfite-treated DNA was amplified within the
Deng C and intron 1 regions with biotin-labeled primers;
the estimated analytical sensitivity was 4% and 5% at C-
region and intron 1, respectively (Additional file 5: Figure
S3A-B). (iv) Clonal bisulfite sequencing of fragments of the
MLH1 promoter encompassing the c.-93G>A promoter
SNP was performed to confirm the low-level methylation
detected by MS-MCA. (v) Finally, genome-wide methyla-
tion profiling was performed using Infinium Human
Methylation 450K Beadchip, as previously described [9].
MLH1 expression and loss of heterozygosity analyses
Human lymphocytes from case 29 were cultured in PB-
MAX Karyotyping Medium (Life Technologies, Carls-
bad, CA) in the absence and presence of puromycin
(Sigma, St. Louis, MO). Puromycin was used to prevent
potential degradation of unstable transcripts by the
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nonsense-mediated decay mechanism. The impact of
MLH1 promoter methylation on allelic expression was
assessed by measuring the relative levels of the two
MLH1 alleles at exonic SNP c.655A>G (rs1799977) in
cDNA/gDNA by single-nucleotide primer extension
(SNuPE), as previously described [18].
Loss of heterozygosity (LOH) was assessed by SNUPE
as the ratio of tumor-DNA/distal normal-DNA at
c.655A>G. Clonal sequencing of MLH1 cDNA was per-
formed to determine the phase between the heterozygous
c.655A>G (exonic) and c.-93G>A (promoter) variants.
Germline mutational analysis
Hereditary cancer genes (including MLH1 gene) were
screened for rare and mosaic germline variants, using
analytical pipelines to detect mosaicism, as described in
Additional file 3: Supplementary Methods.
Immunohistochemical staining analysis
Formalin-fixed, paraffin-embedded tissue sections repre-
sentative of the tumors were studied for CK7, CK20,
CDX2, MUC1, MUC2, and MUC5 protein expression
using standard immunohistochemistry techniques (see
Additional file 3: Supplementary Methods).
Somatic mutational analyses
Mutations in KRAS, NRAS, and BRAF were analyzed in
tumors with the Idylla™ platform (Biocartis, Mechelen,
Belgium). FFPE tumor tissue sections were placed dir-
ectly into the Idylla system cartridge according to the
manufacturer’s instructions (Idylla™ KRAS Mutation
Test and NRAS-BRAF Mutation Test) and were ana-
lyzed for mutations in codons 12, 13, 59, 61, 117, and
146 of KRAS; in codons 12, 13, 59, 61, 117, and 146 of
NRAS; and in codon 600 of BRAF.
Tumor samples were further analyzed using the NGS
customized panel of 126 genes (I2HCP v2.1) as de-
scribed above. To determine somatic variants, germline
variants identified in the paired blood with a variant al-
lele frequency (VAF) > 0.1 were subtracted from tumor
variants. Variant calls with lower than 30x coverage,
VAF < 0.05, or out of the region of interest (gene exons ±
20 bp) were excluded. Somatic variants with VAF > 0.2
in at least one tumor location were considered. The
clonal relatedness between pairs of tumor samples based
on their mutational profiles was tested using the
SNVtest of the Clonality R package, which evaluates evi-
dence for clonality against null hypothesis that the two
tumors are independent [20]. Reference frequencies of
somatic mutations were obtained from TCGA CRC
MSI-H cohort with mutational data available (n = 28)
[21]. For mutations not previously observed in the
TCGA cohort, the reference frequency was set to 0.033
(1/29, being 29 the sum of the TCGA CRC MSI-H cases
plus our patient).
Results
Highly sensitive MLH1 methylation screening
The MS-MCA pattern of MLH1 promoter (region C) of
PBL from DNA healthy controls was the same as the
unmethylated WGA sample, indicating the absence of
detectable methylation in the control group (Add-
itional file 4: Figure S2C). Likewise, 17 out of 18 patients
harboring MLH1-hypermethylated CRC shared a non-
methylated pattern. In contrast, PBL from case 29
showed the presence of methylation at a level of around
1% (Fig. 1a and Additional file 4: Figure S2D). After con-
firmation of the same low methylation levels in an inde-
pendently extracted blood sample (Fig. 1a), we decided
to study the case in depth.
Clinicopathological characterization
Patient 29 is a woman who consecutively presented three
MLH1-methylated gastrointestinal tumor lesions de-
scribed as a low-grade (moderately differentiated) colorec-
tal adenocarcinoma (pT4N1) at age 22, a well-
differentiated small bowel adenocarcinoma (pT4N1) at
age 24, and a well-differentiated tubular adenocarcinoma
of the stomach (pT2N1) at 25 years of age (Fig. 1b). Ac-
cording to the clinical presentation and macroscopic de-
scription, the three lesions were treated as primary
independent tumors. The patient has no disease recur-
rence after 9 years of follow-up. No family history of can-
cer was reported among her first-degree relatives (Fig. 1b).
Of note, the three tumor lesions shared the same im-
munohistochemical staining pattern, showing negative
expression of CK7 and CK20 markers and positive ex-
pression of CDX2, MUC1, MUC2, and MUC3 (Add-
itional file 6: Figure S4). Also, 56% (51 out of 91) of the
somatic variants identified in these lesions were shared
between them, strongly suggesting a common origin
(p < 0.001, clonality package) (Fig. 2a, b). The shared var-
iants included mutations in key genes of intestinal car-
cinogenesis (e.g., APC K562fs, V782fs, and Q205X),
well-known cancer driver mutations (KRAS G12D), and
recurrent homopolymer deletions characteristic of MSI
tumors (e.g., TGFBR2 K153fs).
Confirmation of the mosaic constitutional MLH1
epimutation
The presence of MLH1 methylation was confirmed by
MS-MCA in all embryonic layers since methylation
was detected in endodermal (gastric, small bowel, and
colon mucosa) and ectodermal tissues (oral mucosa
and skin fibroblasts) at similar levels than in PBL
(mesoderm) (Additional file 4: Figure S2). In addition,
slightly higher levels of methylation were also
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detected in normal tissue samples by pyrosequencing,
but below the analytical sensitivity threshold of this
technique (Fig. 1c; Additional file 5: Figure S3). In
contrast, previous MS-MLPA analyses had reported
only background methylation levels in blood DNA
and in normal gastrointestinal tissues (≤ 10%) (Add-
itional file 7: Table S2).
Considering the previous observations, MLH1 methy-
lation in blood was further assessed by clonal bisulfite
sequencing (Fig. 1d) to confirm the presence and density
Fig. 1 Identification and characterization of constitutional MLH1 epigenetic mosaicism in case 29. a Methylation analysis by MS-MCA of the MLH1
promoter C-region in blood DNA from case 29. The patient shows levels of methylation around 1%. b Family pedigree from case 29. The
epimutation carrier is indicated by an arrow. Circles, females; squares, males; filled, cancer affected; vertical line at center, not otherwise specified.
Cancer location and age at diagnosis are indicated. Generations are indicated on the left margin in Roman numerals. c Methylation analysis by
pyosequencing of the MLH1 promoter C-region in blood DNA from case 29 and one healthy control. Each CpG is numbered according its
position relative to the translation initiation codon. d Clonal bisulfite sequencing of the MLH1 promoter in PBL DNA from case 29. Each horizontal
line represents a specific allele. CpG dinucleotides are depicted by circles. Black and white circles indicate methylated and unmethylated CpG
sites, respectively. The allele at rs1800734 (c.-93G>A) is indicated as A or G. Methylation in case 29 is confined to the G allele. Each CpG analyzed
is numbered according to its position relative to the translation initiation codon
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of methylation in individual alleles. Nineteen methylated
clones were identified out of 372 analyzed (5% methyl-
ated alleles; 95% CI 0.01–0.05), all of them displaying
dense monoallelic methylation linked to the G allele at
c.-93G>A (rs1800734), for which patient 29 was hetero-
zygous. Of note, in cis genetic variants on the methyl-
ated G alleles were not detected in the region analyzed,
including c.-27C>A (which has previously been linked to
secondary MLH1 epimutations) [22]. In all, clonal bisul-
fite sequencing supported the robustness of the MS-
MCA results.
Characterization and classification of MLH1 epimutation
Sequencing of MLH1 cDNA clones showed that the mo-
saic methylation of the c.-93G allele was in phase with
the c.655G allele in patient 29 (Fig. 3a). Consistent with
the low percentage of methylation associated with the
c.-93G/c.655G allele, a slight reduction in the expression
of this allele was observed in MLH1 transcripts, as com-
pared to the MLH1 expression in two control individuals
(Fig. 3b). Accordingly, the three tumors showed somatic
LOH on the opposite allele (c.655A) (Fig. 3c).
Global methylome array analysis revealed slightly
higher levels of methylation across the MLH1 promoter
in blood and normal colonic mucosa samples from pa-
tient 29 compared to controls (Fig. 4a, b), encompassing
the same region previously shown to be differentially
methylated in carriers of a constitutional MLH1 epimu-
tation [9].
Of note, germline pathogenic variants were not found
in the coding regions of hereditary cancer genes includ-
ing MLH1 (its promoter sequence was also analyzed) in
patient 29 (Additional file 8: Table S3). Furthermore, no
MLH1 germline copy number alterations were identified
(Additional file 9: Figure S5). These findings, coupled
with the lack of a cancer family history, suggest that pa-
tient 29 is the carrier of a primary epimutation.
Discussion
We report the finding of low-level constitutional MLH1
epigenetic mosaicism in a woman who suffered from three
sequential MLH1-methylated tumor lesions of the upper
abdominal area in her early twenties. A comprehensive
analytical approach that combined highly sensitive MS-
Fig. 2 Somatic mutation profile of the different tumor lesions. a Venn diagram representing the total number of somatic mutations that are
unique to each tumor lesion or shared at least between two tumor lesions. b Type of somatic mutations identified in each tumor sample. Only coding
mutations have been considered. CR, colorectal; SB, small bowel; G, gastric
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MCA with clonal bisulfite sequencing and global methy-
lome array analysis confirmed the presence of dense
allele-specific methylation spanning the entire EPM2AIP1-
MLH1 CpG island in a low proportion (~ 1%) of the
MLH1 alleles (Additional file 10: Figure S6).
Our MS-MCA approach allowed the robust and highly
sensitive detection of MLH1 methylation in blood,
whereas no evidence of methylation was detected in con-
trols. In contrast, pyrosequencing and MS-MLPA, widely
used in clinical diagnostics for MLH1 methylation detec-
tion [12, 14, 23, 24], display a lower analytical sensitivity
(5–10%) than MS-MCA (1%) [19], potentially overlooking
low-level epigenetic mosaicism. Moreover, the back-
ground signal observed in pyrosequencing analyses could
account for the high proportion (78%) of low-level (< 10%)
methylation levels previously reported in healthy controls
[17]. Of note, the presence of constitutional methylation
was only confirmed in one (case 29) of the five patients
showing methylation levels between 1 and 4% by MS-
MLPA (Additional file 2: Table S1). Since MS-MLPA is
based on methylation-sensitive enzymes, incomplete di-
gestion may account for this apparent inconsistency.
Constitutional epigenetic mosaicism in MLH1 is often
observed (reviewed in [9]), in contrast to MMR genetic
mosaicism that has been rarely reported [25–27]. Al-
though several cases with low-level epigenetic mosaicism
of MLH1 (≤ 10% methylation) have been reported [10,
13–16], to date only seven were validated by other tech-
niques. These reported mosaic cases have shown highly
variable clinical phenotypes (Additional file 11: Table
S4), being the case identified herein the most expressive.
Interestingly, our patient was clinically treated consider-
ing the three tumor lesions as non-related primary can-
cers. Retrospectively, a shared origin of the tumors is
highly suggested based on the high percentage of shared
mutations [28–30] and the same immunohistochemistry
CK20-negative pattern, very rare in CRC [31]. This high-
lights the clinical complexity of the case.
We did not identify any genetic alteration associated
with the epimutated allele in case 29, including copy
number variations, promoter variants within the C-D
promoter regions, or other sequencing variants within
MLH1 by Sanger or next-generation sequencing using
mosaicism pipelines. To date, nine families carrying a
Fig. 3 Analysis of the dose of MLH1 alleles at rs1799977 (c.655A>G). a Schematic representation of the MLH1 epimutation found in case 29.
Promoter methylation is associated with the c.-93G allele (in approximately 2% of cells), located in cis with exonic c.655G allele, which showed
subtle reduced transcriptional activity in blood. In concordance, the MLH1 c.655A allele showed LOH in the three tumor lesions developed by the
proband. b Allele-specific expression (ASE) analysis at MLH1 c.655G>A in cDNA derived from leukocytes of case 29 and two heterozygous
controls. A slightly diminished expression of the c.655G allele was observed. c Loss of heterozygosity (LOH) analysis in tumors from case 29. Allele
specific values show loss of the c.655A allele in all three tumors
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secondary epimutation have been described (reviewed in
[8–10]). In one case, the epimutation was present on a
low proportion of alleles (< 10%), associated with the si-
lent variant c.27G>A [10]. Although we cannot com-
pletely rule out that genetic alterations have been
missed, the lack of family history is also compatible with
a de novo primary epimutation. Furthermore, the detec-
tion of similar levels of MLH1 methylation in tissues de-
rived from the three embryonic layers suggests that the
epimutation arose either during early embryogenesis or
as a germline error that was partially erased during early
embryogenesis [5].
The phenotypic expressivity of patient 29 contrasts
with the subtle functional impact on MLH1 expression,
in accordance with the low methylation levels. The pos-
sibility of constitutional MMR deficiency in case 29 was
formally discarded because of the absence of germline
mutations in the promoter and coding regions of MLH1
and the conserved biallelic MLH1 transcription and
MLH1 protein expression in normal tissues. Further-
more, no pathogenic alterations in other hereditary can-
cer genes were detected, although other genetic and/or
environmental factors could be playing a role in the ob-
served phenotype.
Fig. 4 Representation of the differentially methylated region across the MLH1 locus in blood and colorectal mucosa from case 29, MLH1 epimutation
carriers (n= 12), Lynch syndrome genetic mutation carriers (n= 61), and healthy controls (n= 41). Representation of the differentially methylated region
across the MLH1 locus in blood DNA (a) and in normal colorectal mucosa (b). β-values obtained from Infinium 450k Human Methylation array analysis are
displayed as a log (mean β-value × 100) against the genomic coordinate for each CpG site interrogated. The relative locations of the CpG sites are not
drawn to scale. CpG sites are located between Chr3:36,985,516-37,219,077 coordinates. Above, CpG islands (CI) are represented as black rectangles and
their shores are represented in gray. The location of the Deng regions (DR) A, B, C and D of the MLH1 promoter are indicated by white rectangles. Genes
(G) containing the displayed CpG sites are represented as gray rectangles, using the Ensembl GRCh37 database as the reference for gene coordinates
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In contrast to high-level methylation, the potential
contribution of low-level mosaic methylation in blood to
cancer risk remains to be properly assessed [6]. The
combination of soma-wide allelic methylation and asso-
ciated transcriptional silencing in a small proportion of
cells is consistent with the initiation of carcinogenesis
from the ~ 2% cells that contained the epimutation.
Eventually, the somatic loss of the functional (non-meth-
ylated) allele and its clonal expansion would give rise to
each of the MLH1-methylated tumors.
Based on the clinical phenotype and the molecular
profile, intensive surveillance of metachronous gastro-
intestinal and gynecological tumors has been recom-
mended to patient 29 [32]. Also, predictive epigenetic
testing should be proposed to family members. Unless
stable inheritance of hypermethylation could be demon-
strated in descendants (as previously reported [14]), the
estimation of cancer risk in relatives should be cautious
in the absence of an established causal mechanism.
Taking into account the present report, we have iden-
tified three bona fide MLH1 epimutation carriers (two
previously reported in [18] and one in the present study)
among 71 (4.2%) patients with MLH1-methylated CRC
and in three of 20 (15%) patients with early onset or
multiple tumors (Additional file 1: Figure S1). In all,
MLH1 epimutations represent 1% of all LS cases in our
series, including case 29 identified by the use of highly
sensitive techniques.
Conclusion
In summary, we have identified a bona fide case of low-
level MLH1 epigenetic mosaicism by using highly sensi-
tive MLH1 methylation analysis. Considering the ob-
tained results, we strongly recommend the use of highly
sensitive techniques for screening of constitutional
methylation in patients diagnosed with early onset and/
or multiple MLH1-methylated tumors. The eventual
identification and characterization of additional cases
will be critical to ascertain the cancer risks associated
with epigenetic mosaicism.
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Additional file 1. Figure S1. Schematic representation of the origin of
the 18 cases included in this study. CRC: colorectal cancer.
Additional file 2: Table S1. Clinical and molecular features of the
patients with MLH1 methylated tumors included in this analysis.
Additional file 3. Supplementary Methods.
Additional file 4: Figure S2. MLH1 promoter methylation analysis by
Methylation-Specific Melting Curve Analysis (MS-MCA). A) Analytical sensi-
tivity of the promoter C region. The assay displays a sensitivity threshold
of 1%. B) Analytical sensitivity of the promoter D region. The assay shows
sensitivity around 10%. C) Methylation analysis in blood from 10 healthy
controls for the MLH1 C-region. All of them show the same melting curve
pattern as the unmethylated control sample, indicating absence of
methylation in healthy controls. D) Methylation analysis in blood from 18
patients harboring MLH1 methylated tumors for the promoter C region.
Only case 29 displays low levels of methylation (around 1%). E) Methyla-
tion analysis in tumor and normal gastrointestinal tissues of case 29. F)
Methylation analysis in buccal mucosa of case 29. G) Methylation analysis
in skin fibroblasts of case 29.
Additional file 5: Figure S3. MLH1 methylation analysis of the
promoter C-region and intron 1 by pyrosequencing. A) and B) Analytical
sensitivity analysis for the detection of methylation in MLH1 C-region (A)
and intron 1 (B). The detection limits for both regions are 4% and 5% re-
spectively, enabling the detection of positive samples as those with
methylation values greater than 4 or 5%. C) and D) Methylation analysis
in blood from case 29 and healthy controls (n=10 - 20) for the MLH1 C-
region (C) and intron 1 (D). E) and F) Methylation analysis in normal colo-
rectal mucosa from case 29 and Lynch patients (n=4) for MLH1 C-region
(E) and intron 1 (F). G) and H) Methylation analysis in normal small bowel
mucosa and gastric mucosa from case 29 for MLH1 C-region (G) and in-
tron 1 (H). I) and J) Methylation analysis in normal and gastrointestinal
tumor tissues in case 29 for MLH1 C-region (I) and intron 1 (J).
Additional file 6: Figure S4. Immunohistochemical characterization of
gastrointestinal tumor lesions from patient 29. All tumor lesions are well-
differentiated adenocarcinomas with a variable but not predominant mu-
cinous component. All of them present loss of expression of the cytoker-
atin markers CK7 and CK20. The transcription factor CDX2 shows strong
and diffused positive staining. The expression of the membrane-bound
proteins MUC1 and MUC5 is also positive in all tumors but with diffused
and lower intensity staining, whereas the MUC2 shows intense, focal and
heterogeneous expression. According to this characterization, the three
tumors show the same immunohistochemical staining pattern. Objective
magnification is 20X for all images. HE, hematoxylin-eosin.
Additional file 7: Table S2. MLH1 methylation assessed by MS-MLPA in
samples from case 29.
Additional file 8: Table S3. Variants identified in the mutational analysis
of hereditary cancer genes in case 29.
Additional file 9: Figure S5. Analysis of structural aberrations in case
29. A) Genome-wide SNP array profiling of blood DNA from case 29 is
shown as Circos plots. Circos plot was divided into three concentric cir-
cles. Chromosomes are represented at the external circle with their cen-
tromeres painted in red. In the middle circle, external allelic peaks mark
homozygous SNPs and internal allelic peaks heterozygous ones. Internal
circle tracks log2 copy number lane: middle points indicate diploid gen-
omic material; upper points, gains of genomic material and lower points,
losses. Patient 29 displayed a diploid pattern throughout her genome
without signs of loss-of-heterozygosity. B) CNV analysis in the MLH1 re-
gion of patient 29 by custom CGH array. Genes located in the analyzed
region are represented at the bottom of the figure. Probes are displayed
as green dots in a log2 graph. Gains and losses of genetic material are
considered when more than five consecutive probes reach values of 2 or
− 2, respectively. No CNV abnormalities were identified.
Additional file 10: Figure S6. Schematic representation of the
methodological strategy and summary of the obtained results.
Additional file 11: Table S4. Reported patients with MLH1 epigenetic
mosaicism at low proportion (≤10%). (*) According to the obtained
results the three tumor lesions were clonally related.
Additional file 12: Table S5. A. Primers and conditions. B. Localization
of the probes and regions analyzed in the study of MLH1 methylation.
The EMP2AIP1-MLH1 CpG island (colored in dark purple) encompass the
MLH1 promoter and intron 1.
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extension; WGA: Whole Genome Amplification
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